Scholarlink

Background <p>Neoadjuvant chemoradiotherapy (NACRT) is increasingly used for pancreatic ductal adenocarcinoma (PDAC), yet the optimal regimen remains unclear. This phase II trial evaluated the feasibility and efficacy of a short-course NACRT regimen comprising gemcitabine, S-1, and hypofractionated radiotherapy in patients with resectable (R) or borderline resectable (BR) PDAC.</p> Patients and Methods <p>Patients received NACRT with gemcitabine (1000&#xa0;mg/m<sup>2</sup> on days 1 and 8), oral S-1 (60&#xa0;mg/m<sup>2</sup>/day for 14 days), and hypofractionated radiotherapy (30 Gy in 10 fractions over 2 weeks). The primary endpoint was the R0 resection rate. Secondary endpoints included treatment completion, adverse events, tumor response, and survival.</p> Results <p>In total, 54 patients were enrolled. Treatment completion ranged from 87 to 98%. Among 49 patients who underwent resection, 96% achieved R0 resection. A College of American Pathologists tumor regression score of 2 or lower was observed in 49% of tumors. Median follow-up was 24 months. In the intention-to-treat analysis, 1-, 3-, and 5-year overall survival rates were 78, 53, and 42%, respectively. Among resected patients, the median recurrence-free survival was 18 months. Patients with R-PDAC had survival comparable to those reported with longer NACRT regimens, while those with BR-PDAC had less favorable outcomes.</p> Conclusions <p>This short-course NACRT regimen was feasible and yielded favorable survival outcomes, achieving a high R0 resection rate in patients with R-PDAC. By contrast, patients with BR-PDAC may benefit from more intensive treatment, although this requires further validation. These findings support the clinical utility of short-course NACRT and highlight the importance of treatment stratification on the basis of resectability status.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma

  • 期刊论文

  • 发表日期：

    2025年11月18日

查看全文
  • Hironobu Suto,
  • Minoru Oshima,
  • Yasuhisa Ando,
  • Hiroyuki Matsukawa,
  • Shigeo Takahashi,
  • Toru Shibata,
  • Hideki Kamada,
  • Hideki Kobara,
  • Hiroyuki Okuyama,
  • Akihito Tsuji,
  • Kensuke Kumamoto,
  • Keiichi Okano

摘要

Background

Neoadjuvant chemoradiotherapy (NACRT) is increasingly used for pancreatic ductal adenocarcinoma (PDAC), yet the optimal regimen remains unclear. This phase II trial evaluated the feasibility and efficacy of a short-course NACRT regimen comprising gemcitabine, S-1, and hypofractionated radiotherapy in patients with resectable (R) or borderline resectable (BR) PDAC.

Patients and Methods

Patients received NACRT with gemcitabine (1000 mg/m2 on days 1 and 8), oral S-1 (60 mg/m2/day for 14 days), and hypofractionated radiotherapy (30 Gy in 10 fractions over 2 weeks). The primary endpoint was the R0 resection rate. Secondary endpoints included treatment completion, adverse events, tumor response, and survival.

Results

In total, 54 patients were enrolled. Treatment completion ranged from 87 to 98%. Among 49 patients who underwent resection, 96% achieved R0 resection. A College of American Pathologists tumor regression score of 2 or lower was observed in 49% of tumors. Median follow-up was 24 months. In the intention-to-treat analysis, 1-, 3-, and 5-year overall survival rates were 78, 53, and 42%, respectively. Among resected patients, the median recurrence-free survival was 18 months. Patients with R-PDAC had survival comparable to those reported with longer NACRT regimens, while those with BR-PDAC had less favorable outcomes.

Conclusions

This short-course NACRT regimen was feasible and yielded favorable survival outcomes, achieving a high R0 resection rate in patients with R-PDAC. By contrast, patients with BR-PDAC may benefit from more intensive treatment, although this requires further validation. These findings support the clinical utility of short-course NACRT and highlight the importance of treatment stratification on the basis of resectability status.